Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Urología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (INTerpath-004).
INTERVENTIONAL
Inicio: 10 de abr de 2024
ID: NCT06307431
Completado
Fase 2
ClinicalTrials.gov
An Open-label, Multicenter Phase II Study to Examine the Efficacy and Safety of Everolimus as Second-line Therapy in the Treatment of Patients With Metastatic Renal Cell Carcinoma
INTERVENTIONAL
Inicio: 1 de nov de 2011
ID: NCT01491672
Activo, no recluta
Fase 3
ClinicalTrials.gov
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor
INTERVENTIONAL
Inicio: 9 de sept de 2021
ID: NCT04987203
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Active Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis
INTERVENTIONAL
Inicio: 7 de ago de 2019
ID: NCT03840148
Completado
Fase 3
ClinicalTrials.gov
An Open-label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects With Renal Cell Carcinoma Previously Enrolled on Protocol VEG105192
INTERVENTIONAL
Inicio: 1 de sept de 2006
ID: NCT00387764
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment With One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)
INTERVENTIONAL
Inicio: 2 de may de 2019
ID: NCT03834519
Reclutando
Fase 2
ClinicalTrials.gov
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
INTERVENTIONAL
Inicio: 22 de dic de 2016
ID: NCT02960022
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
INTERVENTIONAL
Inicio: 25 de jun de 2019
ID: NCT03937219
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants With Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)
INTERVENTIONAL
Inicio: 2 de may de 2019
ID: NCT03834506
Activo, no recluta
Fase 3
ClinicalTrials.gov
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
INTERVENTIONAL
Inicio: 22 de mar de 2019
ID: NCT03815643
Completado
Fase 3
ClinicalTrials.gov
A Phase 3b Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Women With Chronic Cough and Stress Urinary Incontinence
INTERVENTIONAL
Inicio: 10 de may de 2020
ID: NCT04193176
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)
INTERVENTIONAL
Inicio: 10 de sept de 2025
ID: NCT06919965
Terminado
Fase 3
ClinicalTrials.gov
A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis
INTERVENTIONAL
Inicio: 8 de jul de 2016
ID: NCT02660359
Completado
ClinicalTrials.gov
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
INTERVENTIONAL
Inicio: 1 de jul de 2007
ID: NCT00428220
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
INTERVENTIONAL
Inicio: 1 de jul de 2014
ID: NCT02168946
Activo, no recluta
ClinicalTrials.gov
Darolutamide Observational Study in Non-metastatic Castration-resistant Prostate Cancer Patients
OBSERVATIONAL
Inicio: 30 de ene de 2020
ID: NCT04122976
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized Phase 3 Study Evaluating Cystectomy With Perioperative Pembrolizumab and Cystectomy With Perioperative Enfortumab Vedotin and Pembrolizumab Versus Cystectomy Alone in Participants Who Are Cisplatin-Ineligible or Decline Cisplatin With Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)
INTERVENTIONAL
Inicio: 24 de jul de 2019
ID: NCT03924895
Completado
ClinicalTrials.gov
Multicenter Observational Cohort Study to Evaluate Cerebral AneurysmFlow Results in Occlusion
OBSERVATIONAL
Inicio: 4 de oct de 2018
ID: NCT03663257
Completado
Fase 2
ClinicalTrials.gov
Phase 2 Study of ZK-Epothilone (ZK-Epo; ZK219477) Plus Prednisone as First-line Chemotherapy in Patients With Metastatic Androgen-independent Prostate Cancer
INTERVENTIONAL
Inicio: 1 de ago de 2006
ID: NCT00350051
Reclutando
Fase 2
ClinicalTrials.gov
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer
INTERVENTIONAL
Inicio: 15 de sept de 2023
ID: NCT05951179
Anterior
1
...
13
14
15
...
434
Siguiente
Filtros